State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 510060, Guangzhou, China.
Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann arbor, MI, 48109, USA.
Cell Death Differ. 2020 Jan;27(1):176-191. doi: 10.1038/s41418-019-0351-4. Epub 2019 May 24.
Ischemia-reperfusion (I/R) is a common pathology when the blood supply to an organ was disrupted and then restored. During the reperfusion process, inflammation and tissue injury were triggered, which were mediated by immunocytes and cytokines. However, the mechanisms initiating I/R-induced inflammation and driving immunocytes activation remained largely unknown. In this study, we identified long non-coding RNA (lncRNA)-H19 as the key onset of I/R-induced inflammation. We found that I/R increased lncRNA-H19 expression to significantly promote NLRP3/6 inflammasome imbalance and resulted in microglial pyroptosis, cytokines overproduction, and neuronal death. These damages were effectively inhibited by lncRNA-H19 knockout. Specifically, lncRNA-H19 functioned via sponging miR-21 to facilitate PDCD4 expression and formed a competing endogenous RNA network (ceRNET) in ischemic cascade. LncRNA H19/miR-21/PDCD4 ceRNET can directly regulate I/R-induced sterile inflammation and neuronal lesion in vivo. We thus propose that lncRNA-H19 is a previously unknown danger signals in the molecular and immunological pathways of I/R injury, and pharmacological approaches to inhibit H19 seem likely to become treatment modalities for patients in the near future based on these mechanistic findings.
缺血再灌注(I/R)是一种常见的病理现象,即器官的血液供应被中断然后恢复。在再灌注过程中,炎症和组织损伤被触发,这是由免疫细胞和细胞因子介导的。然而,引发 I/R 诱导的炎症和驱动免疫细胞激活的机制在很大程度上仍然未知。在这项研究中,我们确定长非编码 RNA(lncRNA)-H19 是 I/R 诱导炎症的关键起始物。我们发现,I/R 增加了 lncRNA-H19 的表达,显著促进了 NLRP3/6 炎性小体的失衡,导致小胶质细胞细胞焦亡、细胞因子过度产生和神经元死亡。lncRNA-H19 的敲除有效地抑制了这些损伤。具体来说,lncRNA-H19 通过海绵 miR-21 促进 PDCD4 的表达,并在缺血级联反应中形成竞争内源性 RNA 网络(ceRNET)。lncRNA H19/miR-21/PDCD4 ceRNET 可以直接调节体内 I/R 诱导的无菌炎症和神经元损伤。因此,我们提出 lncRNA-H19 是 I/R 损伤分子和免疫学途径中以前未知的危险信号,基于这些机制研究结果,抑制 H19 的药物方法很可能成为近期内患者的治疗方式。